Q1 EPS Forecast for Halozyme Therapeutics Boosted by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report issued on Tuesday, December 10th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.97 per share for the quarter, up from their prior forecast of $0.95. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q4 2025 earnings at $1.30 EPS, Q1 2026 earnings at $1.40 EPS and Q2 2026 earnings at $1.41 EPS.

Several other research analysts also recently commented on the company. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. HC Wainwright reissued a "buy" rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a report on Monday, November 4th. Finally, JMP Securities increased their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $61.11.

Halozyme Therapeutics Trading Up 1.1 %

Shares of Halozyme Therapeutics stock traded up $0.51 during trading on Thursday, reaching $47.90. The company's stock had a trading volume of 505,449 shares, compared to its average volume of 1,358,123. The company has a market cap of $6.09 billion, a price-to-earnings ratio of 16.06, a PEG ratio of 0.44 and a beta of 1.23. The firm's 50-day moving average is $51.90 and its two-hundred day moving average is $53.93. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at $10,778,084.68. The trade was a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 40,000 shares of company stock worth $2,242,100 over the last 90 days. 2.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of HALO. International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics during the second quarter valued at about $33,000. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $49,000. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 350 shares during the period. Toth Financial Advisory Corp purchased a new position in Halozyme Therapeutics during the third quarter valued at approximately $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $65,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.